Cumberland Pharmaceuticals (NASDAQ:CPIX) Full Year 2024 Results

Key Financial Results

• Revenue: US$37.9m (down 4.3% from FY 2023).
• Net loss: US$6.48m (loss widened by 3.2% from FY 2023).
• US$0.46 loss per share (further deteriorated from US$0.44 loss in FY 2023).

CPIX Products In Clinical Trials

• Phase II: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$35.2m (93% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$17.0m (45% of total expenses). Explore how CPIX's revenue and expenses shape its earnings.

Cumberland Pharmaceuticals shares are down 18% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Cumberland Pharmaceuticals has 2 warning signs (and 1 which can't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.